BioSpace News Archive

Business

Dantari Debuts with $47M to Make Better ADCs

With $47 million in hand, Dantari launched Thursday to advance its Targeted High-capacity Drug Conjugate technology – its take on an antibody-drug conjugate - for solid tumors.

December 8, 2022
·
2 min read
·
Rosemary Scott
Drug Development

‘Dramatic’ Placebo Effect Trips Relmada’s MDD Hopeful for the Second Time

Relmada’s investigational NDMA receptor channel blocker, REL-1017, failed to meet its primary endpoint in major depressive disorder in the Phase III RELIANCE I trial.

December 8, 2022
·
2 min read
·
Tristan Manalac
Business

Vertex Pursues Myotonic Dystrophy with $250M Entrada Deal

Vertex Pharmaceuticals agreed to a collaboration deal with Entrada Therapeutics. The two companies announced a collaboration to develop an intracellular Endosomal Escape Vehicle.

December 8, 2022
·
1 min read
·
George Budwell
Drug Development

Novartis Secures Second Phase III PNH Win in as Many Months

Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) - the company’s second win in this indication in as many months.

December 8, 2022
·
2 min read
·
Mark Terry
Business

Sanofi Backs Out of Revolution Partnership in Latest Cancer Cull

Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,

December 8, 2022
·
2 min read
·
Tristan Manalac
Employer Resources

How to Cope with Setbacks and Stay Positive in an Unpredictable Industry

Those who work in the biopharma industry often see more setbacks than successes. To understand how to overcome failures, BioSpace spoke with two experts on coping with setbacks and staying positive.

December 8, 2022
·
5 min read
·
Gail Dutton
Business

Instil Bio Trashes a TIL Therapy, Cuts 60% of Staff

Instil Bio is discontinuing the development of its unmodified tumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, and laying off 60% of its staff.

December 8, 2022
·
2 min read
·
Alex Keown
Drug Development

Psychedelic Medicine Takes Another Step Forward with Compass’ Twin Updates

Compass’ twin clinical updates regarding its lead candidate spotlight the promise of psychedelic medicine.

December 8, 2022
·
2 min read
·
George Budwell
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

Addex Therapeutics announced that the research term of its collaboration agreement with Indivior PLC for the discovery of novel oral gamma-aminobutyric acid subtype B positive allosteric modulator drug candidates for the treatment of substance use disorder has been extended until June 30, 2023.

December 8, 2022
·
5 min read
Genetown

Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, UK and KU Leuven, Belgium.

December 8, 2022
·
4 min read